SCHEMBL19253528

SCHEMBL19253528

CCOc1nn(Cc2ccc(OC)cc2)cc1C(=O)NC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.50
LMNA P02545 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
RXFP1 Q9HBX9 2/20 0.44
POLB P06746 1/20 0.44
BRD4 O60885 1/20 0.44
DGAT1 O75907 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
AADAT Q8N5Z0 1/20 0.42
SNCA P37840 1/20 0.42
PPARG P37231 1/20 0.42
NCOR2 Q9Y618 1/20 0.42
CACNA1G O43497 1/20 0.41
CACNA1H O95180 1/20 0.41
CACNA1I Q9P0X4 1/20 0.41
KMT2A Q03164 1/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP2C9 P11712 1/20 0.41
KLKB1 P03952 6/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7980023 0.79 KLKB1 (0.60) DGAT1KLKB1
SCHEMBL30953772 0.78 AADAT (0.46) HPGDSMN1; SMN2L3MBTL1AADATSNCA
SCHEMBL25191628 0.77 MAPT (0.47) HPGDLMNAPOLBL3MBTL1AADAT
SCHEMBL25205458 0.76 KMT2A (0.55) L3MBTL1AADATSNCACACNA1GCACNA1H
SCHEMBL25184413 0.76 AADAT (0.47) SMN1; SMN2L3MBTL1AADATSNCACACNA1G
SCHEMBL370661 0.76 KDM4E (0.43) HPGDKMT2AKDM4EALDH1A1KLKB1
SCHEMBL25188719 0.75 AADAT (0.46) SMN1; SMN2POLBL3MBTL1AADATSNCA
SCHEMBL368884 0.75 BLM (0.42) HPGDSMN1; SMN2L3MBTL1AADATSNCA
SCHEMBL370237 0.74 KMT2A (0.47) HPGDSMN1; SMN2POLBL3MBTL1AADAT
SCHEMBL370874 0.74 FLT3 (0.42) HPGDSMN1; SMN2L3MBTL1AADATSNCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10822341-B2 Pyrazolo[1,5-a]pyrazin-4-yl derivatives PFIZER INC. (US) 2020-11-03 US disclosed
US-20190071448-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2019-03-07 US disclosed
US-10144738-B2 Pyrazolo[1,5-A]PYRAZIN-4-YL derivatives PFIZER INC. (US) 2018-12-04 US disclosed
US-20170240552-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2017-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10822341-B2 Pyrazolo[1,5-a]pyrazin-4-yl derivatives CBR3, CNR1, CCR6 HPGD 3950/4885LMNA 3565/4885SMN1; SMN2 3561/4885
US-10144738-B2 Pyrazolo[1,5-A]PYRAZIN-4-YL derivatives JAK1, JAK2, JAK3 HPGD 3426/4885LMNA 3403/4885SMN1; SMN2 4532/4885
US-20170240552-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES CBR3, CNR1, CCR6 HPGD 3950/4885LMNA 3565/4885SMN1; SMN2 3561/4885
US-20190071448-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES CBR3, CNR1, CCR6 HPGD 3950/4885LMNA 3565/4885SMN1; SMN2 3561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.